Compare Restaurant Brands International Inc. Common Shares (QSR) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Restaurant Brands International Inc. Common Shares vs Travere Therapeutics Inc. Common Stock — how do they compare? Restaurant Brands International Inc. Common Shares trades at $72.89 (market cap $24.77B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Restaurant Brands International Inc. Common Shares is far larger — about 4.9× Travere Therapeutics Inc. Common Stock's market cap, and Restaurant Brands International Inc. Common Shares pays a 3.65% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Restaurant Brands International Inc. Common Shares for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| QSR | TVTX | |
|---|---|---|
Market Cap | $24.77B | $5.02B |
Volume | 3,180,422 | 2,060,842 |
Sector | Consumer Cyclical | Health |
52-Week High | $81.67 | $67.52 |
52-Week Low | $65.69 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $39.38B | $5.15B |
Dividend Yield | 3.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QSR trades at $71.27, up 0.21% on the day, with a bearish technical signal driven by moving averages and oscillators. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.08. Revenue reached $9.43B in 2025, with net income of $776M, and is projected to grow to $9.7B in 2026. Analyst consensus is bullish with a price target of $84.80, supported by Burger King's turnaround momentum noted in recent news.
The outlook for QSR is positive due to strong earnings performance and analyst optimism, but near-term technical weakness and competitive pressures pose risks. Investment opportunity lies in execution of the Burger King revitalization and franchise strategy, while risks include market volatility and execution gaps in value offerings against rivals like McDonald's.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Restaurant Brands International Inc. Common Shares
Restaurant Brands International owns and franchises quick-service restaurant brands, including Burger King, Tim Hortons, Popeyes, and Firehouse Subs.
Read more on QSR →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
